Important predictors of adverse outcomes of thrombosis in children, including the postthrombotic syndrome (PTS), have recently been identified. Given this knowledge and the encouraging preliminary pediatric experience with systemic thrombolysis, we sought to retrospectively analyze our institutional experience with a thrombolytic regimen versus standard anticoagulation for acute, occlusive deep venous thrombosis (DVT) of the proximal lower extremities in children in whom plasma factor VIII activity and/or D-dimer concentration were elevated at diagnosis, from within a longitudinal pediatric cohort. Nine children who underwent the thrombolytic regimen and 13 who received standard anticoagulation alone were followed from time of diagnosis with serial clinical evaluation and standardized PTS outcome assessments conducted in uniform fashion.
For personal use only. on September 24, 2017 . by guest www.bloodjournal.org From ABSTRACT Important predictors of adverse outcomes of thrombosis in children, including the postthrombotic syndrome (PTS), have recently been identified. Given this knowledge and the encouraging preliminary pediatric experience with systemic thrombolysis, we sought to retrospectively analyze our institutional experience with a thrombolytic regimen versus standard anticoagulation for acute, occlusive deep venous thrombosis (DVT) of the proximal lower extremities in children in whom plasma factor VIII activity and/or D-dimer concentration were elevated at diagnosis, from within a longitudinal pediatric cohort. Nine children who underwent the thrombolytic regimen and 13 who received standard anticoagulation alone were followed from time of diagnosis with serial clinical evaluation and standardized PTS outcome assessments conducted in uniform fashion.
The thrombolytic regimen was associated with a markedly decreased odds of PTS at 18-24 months when compared to standard anticoagulation alone, which persisted after adjustment for significant covariates of age and lag time to therapy (OR=0.018, 95% CI=<0.001-0.483; P=0.02). Major bleeding developed in one child, judged clinically as not directly related to thrombolysis for DVT. These findings suggest that the use of a thrombolysis regimen may safely and substantially reduce the risk of PTS in children with occlusive lower-extremity acute DVT, providing the basis for a future clinical trial.
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INTRODUCTION
Over the past few decades, deep venous thrombosis (DVT) has emerged as a critical issue in pediatrics (1) (2) (3) . While the incidence of DVT is substantially lower among children than adults, with a recent rate of five cases per 10,000 children per year from the National Hospital Discharge Survey, it is clear that many cases of DVT and pulmonary embolism (PE) go unrecognized in part due to a low index of suspicion for young patients; consequently, these conditions are likely under-diagnosed in children (4, 5) . At the same time, the consequences of DVT and PE in children are significant. Sixteen to 20% of children with venous thromboembolism (VTE) have objectively-confirmed PE (2, 5, 6) , and the mortality rate for major vessel thrombosis in children is estimated at 1 to 4% (2, 3, 6, 7) . Thrombus recurrence has been reported in 6.5 to 21% of children with VTE (2, 3, (6) (7) (8) . Finally, the post-thrombotic syndrome (PTS), a syndrome of chronic venous insufficiency often associated with limitation in physical activities (9, 10) , appears to develop following DVT of the limbs at least as frequently in children as adults, with reports of up to 70% of children affected (2, 3, 6, 7, (11) (12) (13) (14) (15) . Comprehensive pediatric thrombosis centers have just recently been formed to address these and other key concerns of thrombosis in children (6) (7) (8) 16 ).
Given prior evidence of a positive relationship between thrombus persistence and the development of PTS following DVT in adults (17, 18) , the identification of elevations in D-dimer and factor VIII (FVIII) activity as prognostic indicators for thrombus persistence and recurrence in adults (19, 20) and as predictors of composite adverse thrombotic outcomes in children (persistent thrombosis, recurrent VTE, and PTS) (13) , preliminary findings of safety and efficacy of thrombolysis with or without mechanical thrombectomy (particularly with regard to the reduction in PTS risk) in the acute treatment of symptomatic lower extremity DVT in adults (21) (22) (23) , and pilot data on (24, 25) , we sought to retrospectively analyze our single-institutional experience with thrombolysis followed by standard anticoagulation versus standard anticoagulation alone for high-risk, occlusive, first-episode, acute DVT of the lower extremities from within the context of a longitudinal pediatric cohort. We hypothesized that therapy consisting of thrombolysis followed by standard anticoagulation is associated with decreased odds for the development of PTS in children with high-risk occlusive DVT of the lower extremities when compared to anticoagulation alone, and that age at DVT diagnosis and lag time from symptom onset to institution of antithrombotic therapy are important additional clinical factors modulating PTS risk in such children.
PATIENTS, MATERIALS AND METHODS
In 2001 a comprehensive pediatric program for thrombosis and/or thrombophilia was established at the Mountain States Regional Hemophilia and Thrombosis Center (MSRHTC) and The Children's Hospital, Denver, with funding from the Centers for Disease Control and Prevention (CDC). Children in the present analysis were referred to the thrombosis program at the time of presentation with an acute DVT of the proximal lower extremity. All children were followed forward in time from initial diagnosis until at 
Study group eligibility and baseline laboratory testing
Inclusion criteria for the present study consisted of: (1) radiologically-confirmed, completely veno-occlusive, first-episode, acute DVT of the lower extremity with or without extension into the inferior vena cava; (2) measured plasma FVIII activity ≥ 150 U/dL and/or D-dimer ≥ 500 ng/mL; (3) age at DVT diagnosis ranging from six months to 21 years, inclusive; (4) complete data available for antithrombotic treatment and anticoagulant monitoring during the antithrombotic therapy period, serial follow-up Thrombosis and Haemostasis (27) .
Treatment
Thrombolytic therapy consisted of one of two regimens ( Figure 1 ): (1) initial systemic intravenous administration of low-dose tissue-type plasminogen activator (tPA) with delayed mechanical thrombolysis and local (catheter-directed) tPA via an interventional radiologic approach; or (2) local (catheter-directed) administration of tPA with mechanical thrombolysis via an interventional radiologic approach. These thrombolytic regimens have been recently described (16) and are summarized in Figure 1 , with the goal of rapid restoration of venous patency. In the case of systemic tPA, infusion was begun at 0.03 mg/kg/hr with concomitant intravenous administration of unfractionated heparin at 10 U/kg/hr, with the option to increase the tPA dose to 0.06 mg/kg/hr at 24-48 hrs for radiologic evidence of persistent thrombus, up to a maximum tPA rate of 2 mg/hr. Systemic tPA infusion was discontinued upon radiologic documentation of complete thrombus resolution, and was continued for a minimum of 48 hours in the In all children, contraindications to the use of anticoagulation or thrombolysis were carefully assessed and consistently enforced, as previously described (16) . PT, aPTT, fibrinogen, D-dimer, hematocrit, platelet count and plasminogen were measured daily during systemic tPA infusion, and fresh frozen plasma, cryoprecipitate, and/or platelet concentrates administered as needed to maintain PT < 3 seconds above the upper limit of normal; fibrinogen > 100 mg/dL, platelet count > 50,000/µL, and plasminogen concentration > 50 U/dL.
Initial anticoagulation for children on standard therapy or following thrombolysis consisted of unfractionated heparin adjusted to achieve a plasma anti-Xa activity of 0.3-0.7 U/mL or enoxaparin adjusted to 0.5-1.2 anti-Xa activity U/mL for at least seven days.
Long-term anticoagulation was maintained with enoxaparin or warfarin, with goal antiXa activity of 0.5-1.2 U/mL or INR of 2.0-3.0 (2.5-3.5 if antiphospholipid antibody positive), respectively, for a minimum total anticoagulation therapy duration of three (26) . Indications for further extension of anticoagulant therapy included antiphospholipid antibody syndrome, severe congenital thrombophilia, or multiple thrombophilia traits. Extension of anticoagulation was also considered as an option in cases of persistent occlusive thrombosis at three months. 
Laboratory methods

Plasma
Radiologic imaging
Both at diagnosis and serial follow-up, compression ultrasound with Doppler was the primary modality used to image the extent and occlusiveness of lower extremity DVT, with additional computerized tomography used to define the extent and occlusiveness of iliac venous and/or inferior vena caval involvement not visualized by ultrasound. Serial follow-up imaging to determine thrombus response to therapy was performed at one, three, six and twelve months.
Standardized PTS outcome assessment
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Children were evaluated for PTS at one, three, six, and twelve months and then yearly using a standardized PTS outcome instrument (28) . This scoring system encompasses assessment of both physical examination findings and functional limitations (i.e., chronic lower extremity pain that limits age-appropriate activity), and was derived from the validated international adult PTS scale of the American Venous Forum's Ad Hoc Committee on Venous Outcomes (10), with minor adaptation for pediatric application.
Specifically, the modification consisted of the use of the Wong-Baker Faces Pain Scale previously validated for pain assessment in children (29) . Data for the validation of this instrument for lower extremity DVT in children are given below (Results).
Physical outcome was scored as zero for no physical findings of chronic venous insufficiency. Individual findings of edema (>1 cm increase in mid-calf or mid-thigh circumference in the affected extremity when compared to the contralateral extremity), dilated superficial collateral veins, venous stasis dermatitis, and venous stasis ulcers were each assessed one point, for a maximum physical exam score of four.
Functional limitation due to chronic lower extremity pain was scored for each of three levels of activity: none (i.e., rest); activities of daily living (e.g., walking at school or home, climbing steps); and aerobic activity (e.g., running on the playground, participation in organized sports), with one point given for pain-limitation to each activity or at rest.
PTS was defined as a composite (physical exam plus functional assessment) score of one or more, and abnormalities in the two components of the instrument were also separately reported and analyzed.
Assessment of bleeding complications
Bleeding was monitored clinically in an inpatient setting during the acute antithrombotic period and both by history and clinical exam upon serial follow-up as an outpatient throughout the extended anticoagulation therapy period (at one and three months in all patients, and additionally at six and twelve months and annually thereafter in patients who met clinical criteria for long-term anticoagulation). Medical records were requested and reviewed for any bleeding events for which treatment was sought at outside facilities.
Bleeding episodes were defined as "major" if any of the following four circumstances existed, as previously established (30): (1) CNS hemorrhage; (2) retroperitoneal hemorrhage; (3) hemorrhage associated with a decline in hemoglobin of ≥ 2g/dL in a 24 hour period; (4) hemorrhage prompting surgical intervention to achieve hemostasis.
Minor bleeding episodes, including bruising or oozing at venipuncture sites, were not systematically recorded and analyzed.
Statistical methods
In the validation of the PTS instrument for lower extremity DVT, descriptive statistics were employed in order to establish distributions and corresponding parameters of normal contralateral differences in lower extremity circumference measurements in healthy children. The upper limit of normal values for these differences was calculated using the expression median + (1.5*interquartile range), given non-parametric distribution of these data. Inter-rater reliability was measured by percent agreement, calculated as the number of agreeing observations divided by the total number of observations, and multiplied by one hundred.
All statistical analyses in the study cohort used SAS 9.1 statistical software (SAS Institute, Cary, NC). Descriptive statistics were employed for explanatory variables (consisting of known and hypothesized risk factors for and prognostic indicators in DVT and PTS) in order to define distributions and corresponding parameters of continuous variables and frequencies and proportions of categorical variables by treatment regimen.
These distributions and proportions were compared between treatment regimens 
RESULTS
Validation of the PTS instrument for lower-extremity DVT in children
All parameters of the PTS instrument were formally assessed in a separate derivation cohort (n=78) consisting of healthy children aged 12 months to 21 years who were without known underlying medical conditions, were taking no medications, and had no personal or first-degree family history of venous thromboembolism, myocardial infarction, or ischemic stroke prior to 55 years of age. The age-grouped distributions of these findings in the derivation cohort are shown in Table 1 . Based upon these observations, the upper limit of normal for the contralateral difference in lower extremity circumference was determined to be 1.0 cm for mid-thigh and mid-calf, irrespective of age group. This value was then uniformly employed in the evaluation of presence versus absence of lower extremity edema in patients with DVT in the present study.
Furthermore, dilated superficial collateral veins, venous stasis dermatitis, venous stasis ulcers and chronic lower extremity pain limiting aerobic activities, activities of daily living or at rest were all found to be absent in the derivation cohort, such that their presence was defined as abnormal on the physical exam and pain components of the PTS instrument when uniformly employed in patients with DVT in the present study.
Inter-rater reliability in each parameter of the PTS instrument was evaluated in a cohort (n=50) comprised of both healthy children as described above and children with a history of lower extremity DVT aged 12 months to 21 years. PTS assessment using the standardized pediatric outcome instrument was independently performed by two trained clinicians who were blinded to each other's findings. Values for inter-rater-reliability, measured as percent agreement, are given in Table 2 . Tables 3   and 4 for each patient. Based upon clinical judgment, nine of these children were treated by thrombolysis and 13 by standard anticoagulation alone. Among the former group, seven received systemic tPA (two of whom underwent salvage mechanical thrombectomy with additional local, catheter-directed tPA) and two underwent local thrombolysis alone, via mechanical thrombectomy and catheter-directed tPA. One child (subject #9) in whom systemic tPA infusion was prematurely discontinued due to need for an invasive procedure was maintained in the analysis, as was one child (subject #7) in whom systemic tPA was prematurely discontinued and a subsequent course of standard anticoagulation was withheld due to a minor hemorrhagic complication (see Bleeding complications, below). Two children treated with systemic thrombolysis alone had been included in earlier reports (24, 25) . Table 5 summarizes patient characteristics, including hypothesized and known risk factors for and prognostic indicators in pediatric DVT and PTS, by treatment group (thrombolytic therapy followed by standard anticoagulation versus standard anticoagulation alone). As shown in the table, the two treatment groups were wellmatched for all characteristics, with the exception that the proportion of patients having concomitant PE at DVT diagnosis was significantly greater in the thrombolytic regimen group than the standard anticoagulation group (44.% vs. 7.7%, respectively; P=0.04). 
Study groups
indwelling CVC, presence of the lupus anticoagulant (LA), antiphospholipid antibody syndrome, non-LA thrombophilia, or genetic thrombophilia in particular.
Outcomes
As shown in Table 5 
30.8%), this difference appears to be clinically meaningful.
In univariate logistic regression (Table 6 ), treatment regimen was significantly and most strongly associated with PTS (P=0.02). The thrombolytic regimen was associated with a markedly decreased odds of PTS (OR=0.086, 95% CI=0.011-0.655) when compared to standard anticoagulation alone, representing a 91% decrease in the odds of PTS. In addition, thrombus resolution (≥ 90% versus < 90% clot resolution at one year) was significantly associated with the development of PTS, such that the odds of PTS were 91% decreased in children who exhibited complete or near-complete thrombus resolution
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CI=0.008-0.960; P=0.046).
Multivariate analysis evaluated the odds of PTS for the primary explanatory variable (therapy regimen) after adjustment for those explanatory variables that were hypothesized a priori to be important explanatory variables (specifically, age at DVT diagnosis and lag time from symptom onset to initiation of antithrombotic therapy) as well as those explanatory variables found to be potentially statistically significant (using a threshold of P<0.2) by univariate logistic regression. Interestingly, the former two variables (age and lag time to therapy) were also the only additional explanatory variables that met the latter criterion for inclusion in multiple logistic regression (P=0.10 and P=0.20, respectively; Table 5 ). Explanatory variables that were in the a priori hypothesized causal pathway of the relationship between therapy regimen and PTS development (specifically, thrombus resolution) were accordingly not included in the multivariate model. Importantly, after adjustment for age and lag time to therapy, therapy regimen was significantly and independently associated with the development of PTS (P=0.02). The thrombolytic regimen remained associated with a markedly decreased odds of PTS (OR=0.018, 95% CI=<0.001-0.483) when compared to standard anticoagulation alone, representing a 98% decrease in the odds of PTS.
Bleeding complications
Major bleeding complications occurred in one child with near-complete occlusion of both proximal pulmonary arteries due to PE at the time of acute DVT, resulting in rapidlyprogressive right-heart failure. This patient suffered a pulmonary hemorrhage in association with pulmonary arterial mechanical thrombolysis. He was successfully supported with packed red blood cell transfusion and continuous positive airway pressure
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From via mechanical ventilation to tamponade the pulmonary hemorrhage, and is alive and well seventeen months following the event. Notably, this bleeding event was clinically judged to be related to the emergent pulmonary arterial mechanical thrombolytic procedure (immediately prior to which systemic tPA was discontinued), rather than directly to the thrombolytic regimen for DVT per se. An additional child was noted to develop a pelvic hematoma near the site of recent femoral CVC placement, a minor procedure for which administration of systemic tPA had been judged clinically to present an acceptable risk of bleeding; this bleeding episode did not meet criteria for a major bleeding episode (see Methods, above).
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DISCUSSION
Thrombolysis has been applied to the treatment of venous thrombosis in children for twenty years (24, 25, (31) (32) (33) , albeit in highly limited and selected fashion. Until recently, the use of thrombolysis in adults with venous thrombosis (in whom local thrombolysis is primarily employed) has been reserved for thrombi that are life-or limb-threatening, or that have progressed on standard anticoagulant therapies. Broad application of thrombolysis to DVT has not yet occurred, primarily due to concerns regarding major hemorrhagic complications of thrombolysis and the need to appropriately risk-stratify patients who are most likely to benefit from this intensive management approach.
Recently, it has been recognized that risk of major hemorrhage related to thrombolytic therapy is relatively low in young patients when appropriate contraindications are strictly observed (21) (22) (23) (24) (25) . Although the risk for bleeding (including both major and minor hemorrhage) is increased for systemic tPA as compared to standard anticoagulation, careful selection of patents, diligent surveillance for signs of possible bleeding complications, and proactive management of hemorrhage can all render this risk quite acceptable, given the observation that the rate and severity of post-thrombotic syndrome following DVT appears to be decreased when venous flow is rapidly restored via thrombolysis (23) . Finally, biomarkers such as FVIII and D-dimer have emerged as prognostic indicators in venous thrombosis, in turn making risk-stratification more feasible (13, 19, 20) .
To date, published pediatric data regarding the safety of thrombolysis (whether systemic or local, and with or without mechanical thrombectomy) are limited, and its efficacy in the prevention of PTS in children has not been evaluated. We previously reported decreased signs of PTS in children treated with urokinase thrombolysis in whom > 75% restoration in venous blood flow was achieved within 48 hours of initiation of therapy (25) . Based on our encouraging preliminary experience with systemic thrombolysis in a small number of children with extremity DVT, we developed a thrombolytic management paradigm aimed at achieving rapid restoration of venous blood flow in children with occlusive lower extremity DVT. We employed a step-wise approach to venous flow restoration typically beginning with systemic low-dose continuous intravenous infusion of tPA and employing local mechanical thrombectomy with catheter-directed tPA administration as salvage therapy for persistent thrombosis. In some instances, the same local thrombolytic approach was used without prior systemic tPA administration. The current report is among the first to describe thrombus resolution and PTS outcomes of thrombolysis for a subset of children in whom mechanical thrombolysis was specifically used.
The present data support our prior findings that, in the context of a rigorously-applied clinical pathway, thrombolysis appears to be appropriately safe in children with completely veno-occlusive lower extremity DVT. Furthermore, the present findings suggest that the use of a thrombolysis regimen may substantially reduce the risk of PTS in children with occlusive lower-extremity acute DVT and plasma levels of FVIII activity ≥ 150 U/dL and/or D-dimer concentration ≥ 500 ng/mL. In this cohort study analysis, in which treatment groups were well-matched for VTE risk factors and prognostic indicators at DVT diagnosis, we observed a 98% relative reduction in the odds of PTS for children treated with the thrombolytic regimen followed by standard anticoagulation as compared to standard anticoagulation alone, after adjustment for both age at DVT diagnosis and lag time from symptom onset to institution of antithrombotic therapy.
Seventy-seven percent of children in the standard anticoagulation group developed PTS, as compared to only 22% in the thrombolytic group. While a statistically significant difference in the proportion of patients who developed moderate-severe PTS was not
clinically significant, and the detection of statistical significance is likely impaired by the relatively small size of the study population. Furthermore, it is worthy of note that the only child in the thrombolytic group who developed moderate-severe PTS (subject #9, who was also the only child in this group in whom thrombus persisted at one year), had experienced a lag time of greater than one month from onset of symptoms to initiation of antithrombotic therapy, and had received only an abbreviated course of systemic tPA due to the need for an invasive procedure.
Several limitations of the study must be recognized. Given the rather small number of children treated by the thrombolytic regimen, accurate measurement of safety with respect to bleeding complications is limited, and firm conclusions as to safety should await formal analysis of safety data derived from a clinical trial. Secondly, the treatment allocation in this study was determined clinically, and was non-randomized, such that selection biases are possible. However, statistical analyses revealed that the two treatment groups were well-matched with respect to possible predictor variables of age, lag time to therapy, and frequencies of central venous catheter association, genetic thrombophilia, lupus anticoagulant positivity, antiphospholipid antibody syndrome, and non-lupusanticoagulant acquired thrombophilia. Nevertheless, it is reasonable to postulate that children with greatest severity of thrombosis and judged at highest risk for PTS were most likely to be chosen for thrombolytic therapy, such that children in the thrombolytic group might have been at increased a priori risk for PTS. The significantly higher prevalence of PE in the thrombolytic group supports this notion.
An additional limitation of the present analysis is that thrombolytic outcomes were summarized for children treated either by continuous systemic low-dose tPA with subsequent local thromboysis as salvage therapy, or by local thrombolysis without prior systemic tPA. Given the size of the study population, trends toward superiority of one of the two approaches cannot be detected; however, for optimal design and analysis, a future clinical trial should preferably employ only one of the two approaches. Furthermore, the feasibility of mechanical thrombolysis is limited by both local expertise and size constraints of the child. The smallest child treated in this series treated with mechanical thrombolysis via an interventional radiologic approach was twenty-nine kilograms.
However, infants as small as ten kilograms with acute venous thrombosis have been treated by mechanical thrombolysis in our thrombosis program, in the case of superior vena cava obstruction.
When evaluating the applicability of the present analysis, it is important to consider both the risk and potential benefits of thrombolytic therapy. Because children require venous sufficiency and capacity for aerobic exercise for normal growth and development, the negative impact of PTS will be especially pronounced in children. Furthermore, because children are anticipated to live six or more decades following an episode of acute DVT, the long-term costs and morbidity of PTS are likely to be substantial. On the other hand, the bleeding risks of aggressive antithrombotic therapies such as systemic and/or local thrombolysis are not so well understood in children as to permit their broad application.
The current finding that a thrombolytic regimen is associated with a statistically significant decrease in the odds of PTS in general, but not in the odds of PTS that involves both physical exam abnormalities and functional limitation (perhaps due to the relatively small size of the study population), emphasizes the need to select the highest Data for contralateral differences in circumference are given as median (range).
Note:
In each age group, the prevalences of dilated superficial collateral veins, venous stasis dermatitis, venous stasis ulceration, chronic lower extremity pain limiting aerobic activities, chronic lower extremity pain limiting activities of daily living, and chronic lower extremity pain at rest were all 0%.
Abbreviations: PTS, post-thrombotic syndrome. Abbreviations: PE, pulmonary embolism; FVIII, factor VIII activity; APA, antiphospholipid antibody; PTS, post-thrombotic syndrome.
PTS was uniformly assessed at 18-24 months post-diagnosis of deep venous thrombosis, and consisted of either physical exam abnormalities, functional limitations, or both (i.e., PTS score ≥ 1; see Methods), except as otherwise noted. Lag to therapy represents time from symptom onset to institution of antithrombotic therapy. Acquired thrombophilia excludes FVIII activity, D-dimer concentration, and the presence of the lupus anticoagulant, which are given separately. Thrombus resolution indicates ≥ 90% thrombus resolution as documented radiologically at one year post-diagnosis of deep venous thrombosis. Statistically significant differences are shown in boldface type. Thrombolytic therapy is compared to standard anticoagulation.
Abbreviations: PE, pulmonary embolism; FVIII, factor VIII activity; APA, antiphospholipid antibody; PTS, post-thrombotic syndrome.
PTS was uniformly assessed at 18-24 months post-diagnosis of deep venous thrombosis. Lag to therapy represents time from symptom onset to institution of antithrombotic therapy. Acquired thrombophilia excludes FVIII activity, D-dimer concentration, and the presence of the lupus anticoagulant, which are given separately. Thrombus resolution indicates ≥ 90% thrombus resolution as documented radiologically at one year post-diagnosis of deep venous thrombosis. Statistically significant associations are shown in boldface type.
